GGrantIndex
← Search

RADIATION RESOURCES CORE

$72,476P30FY2010CANIH

Case Western Reserve University, Cleveland OH

Investigators

Linked publications, trials & patents

Trial NCT05340673Trial NCT05198830Trial NCT02590107Trial NCT02535325Trial NCT02451124Trial NCT02419846Trial NCT02417948Trial NCT02392377Trial NCT02388932Trial NCT02383433Trial NCT02375477Trial NCT02354326Trial NCT02345460Trial NCT02342730Trial NCT02337465Trial NCT02327390Trial NCT02319889Trial NCT02307474Trial NCT02287636Trial NCT02252393Trial NCT02181478Trial NCT02179762Trial NCT02163317Trial NCT02158767Trial NCT02153450Trial NCT02135562Trial NCT02131207Trial NCT02129582Trial NCT02129569Trial NCT02129517Trial NCT02129218Trial NCT02128373Trial NCT02108587Trial NCT02100423Trial NCT02084147Trial NCT02082405Trial NCT02081794Trial NCT02079155Trial NCT02073097Trial NCT02073045Trial NCT02071901Trial NCT02070458Trial NCT02070419Trial NCT02055586Trial NCT02037048Trial NCT01973062Trial NCT01959490Trial NCT01959477Trial NCT01954784Trial NCT01954732Trial NCT01951885Trial NCT01939028Trial NCT01928485Trial NCT01894061Trial NCT01408043Trial NCT00991991Trial NCT00970684Trial NCT00961220Trial NCT00956475Trial NCT00952939Trial NCT00949247Trial NCT00945061Trial NCT00941720Trial NCT00941070Trial NCT00939510Trial NCT00918892Trial NCT00918788Trial NCT00918658Trial NCT00918216Trial NCT00910039Trial NCT00909662Trial NCT00908739Trial NCT00908141Trial NCT00907699Trial NCT00905086Trial NCT00900133Trial NCT00899158Trial NCT00899132Trial NCT00898573Trial NCT00898274Trial NCT00897143Trial NCT00892385Trial NCT00873600Trial NCT00873002Trial NCT00866320Trial NCT00856115Trial NCT00853021Trial NCT00842452Trial NCT00809185Trial NCT00796978Trial NCT00795678Trial NCT00769951Trial NCT00769249Trial NCT00752323Trial NCT00740961Trial NCT00736216Trial NCT00735514Trial NCT00733252Trial NCT00732745Trial NCT00732173

Abstract

The Radiation Resources Core Facility (RRCF) provides an essential service to the Cancer Center, since ionizing radiation has both carcinogenic and therapeutic roles in cancer and can produce viable, but nonreproductive cells tor a variety of other studies. The Facility serves two types of cancer researchers: those studying the cancer-causing and cancer-treating actions of radiation, and those with primary interests in other topics for whom radiation is an essential tool, e.g. for killing cells to prepare feeder layers for growth of embryonic stem cells, or to study the immunogenic properties of cancer cells. The RRCF is directed by Nancy L. Oleinick, PhD, and managed by John Mulvihill, MS, both of whom have held these positions since the founding of the Cancer Center. The objectives of the RRCF are: (1) To maintain and operate ionizing radiation-producing devices for cancer researchers; (2) To consult with users concerning the instrumentation, the services, the training requirements, and if desired, the experimental design (3) To train new users in proper operation of the equipment;and (4) To document usage by keeping and reviewing user logs. The RRCF provides three gamma-irradiators, two located in a 256-sq. ft. room in Cancer Center space in the Biomedical Research Building (BRB), and one located in a 58-sq. ft. area within the barrier facility of the Cancer Center's Athymic Animal Facility in the Wolstein Research Laboratories. A low-dose-rate lr-192 irradiator is housed in a shielded inner room within the BRB area. Ancillary equipment for cell handling is also provided in Cancer Center space adjacent to the BRB irradiator room. Mr. Mulvihill trains users in the proper and safe use of the irradiators and occasionally carries out irradiations for users when requested. Dr. Oleinick consults with users on protocols and dosages to accomplish their research goals. Because of cost, licensing, and requirement for expertise, it would be impractical for the many cancer researchers to maintain their own irradiators;thus, this facility provides essential equipment and service to cancer researchers in an efficient and cost-effective manner.

View original record on NIH RePORTER →